As of 2026-02-04, 瑞美吉泮（乐泰可）'s data on the DeepSeek platform in the 偏头痛急性治疗药物 category shows: The overall mention rate is 0.00%, below the industry average by 33.0 percentage points, with significant room for improvement. The first mention rate is only 0.00%, it is recommended to enhance first-position exposure in AI model responses. Negative mention rate (0.00%) has exceeded positive (0.00%), it is recommended to immediately initiate reputation repair. AIGeo recommends combining the above data to formulate targeted brand monitoring strategies to further enhance brand visibility and reputation in the AI search ecosystem.
瑞美吉泮（乐泰可）'s Mention Rate is 0.00%, lower than 0.6% of competitors
瑞美吉泮（乐泰可）'s First Mention is 0.00%, lower than 0.9% of competitors
瑞美吉泮（乐泰可）'s Preferred Rate is 0.00%, lower than 100.0% of competitors
瑞美吉泮（乐泰可）'s Positive Rate is 0.00%, lower than 8.9% of competitors
瑞美吉泮（乐泰可）'s Negative Rate is 0.00%, higher than 96.3% of competitors
| Competitor | Mention Rate | First Mention | Preferred Rate | Positive Rate | Negative Rate | Actions |
|---|---|---|---|---|---|---|
| 瑞瑞美吉泮（乐泰可） (Current Brand) | 0% | 0% | 0% | 0% | 0% | View Details |
